Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MPO | P05164 | 2/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15107549 | 0.84 | GABRA1 (0.45) | GABRA1GABRB2RIPK1TAAR1 | |
| SCHEMBL803448 | 0.84 | TAAR1 (0.48) | RIPK1TAAR1NR3C1NR3C2GAA | |
| Ammonia Solution, Strong SCHEMBL27962085 | 0.82 | TAAR1 (0.46) | RIPK1TAAR1NR3C1NR3C2GAA | |
| SCHEMBL347746 | 0.82 | GABRA1 (0.61) | GABRA1GABRB2RIPK1IDO1 | |
| SCHEMBL18647605 | 0.79 | TAAR1 (0.35) | RIPK1TAAR1NR3C1NR3C2MAOB | |
| SCHEMBL314108 | 0.76 | GABRA1 (0.54) | GABRA1GABRB2RIPK1 | |
| SCHEMBL20988671 | 0.74 | RIPK1 (0.47) | RIPK1TAAR1NR3C1NR3C2L3MBTL1 | |
| SCHEMBL27009991 | 0.73 | GABRA1 (0.47) | GABRA1GABRB2RIPK1 | |
| SCHEMBL19388206 | 0.73 | RIPK1 (0.42) | RIPK1TAAR1NR3C1NR3C2L3MBTL1 | |
| SCHEMBL27962084 | 0.73 | TAAR1 (0.52) | RIPK1TAAR1NR3C1NR3C2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265045-A1 | PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS | PNMT, HTR2C, HTR2A | GABRA1 201/4885GABRB2 105/4885RIPK1 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.